Non-channel drugs to prevent atrial fibrillation;A pitvarfibrilláció nem ioncsatornára ható gyógyszeres kezelése

Orvosi Hetilap

Volumn 146, Issue 45, 2005, Pages 2287-2294

  Fazekas, Tamás ^a,c   Liszkai, Gizella ^b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b Bekes Megyei Kepviselo testulet Pandy Kalman Korhaz   (Hungary)

^c NONE   (Hungary)

Author keywords

Atrial fibrillation; Non channel pharmacological treatment; Structural remodelling

Indexed keywords

ALDOSTERON ANTAGONIST; ANGIOTENSIN II AT1 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIFIBROTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANTIINFLAMMATORY AGENT; POTASSIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL BLOCKING AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART MUSCLE CELL; HUMAN; MORTALITY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SIGNAL TRANSDUCTION; DRUG EFFECT; HEART ATRIUM; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ANTI-INFLAMMATORY AGENTS; ATRIAL FIBRILLATION; HEART ATRIA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; POTASSIUM CHANNEL BLOCKERS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECURRENCE; SODIUM CHANNEL BLOCKERS;

EID: 33644819425     PISSN: 00306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Becker, A. E.: How structurally normal are human atria in patients with atrial fibrillation? Heart Rhythm, 2004, 1, 627-631.
2. Brundel, B. J. J. M., Kampinga, H. H., Henning, R. H.: Calpain inhibition prevents pacing-induced cellular remodeling in a HL-1 myocyte model for atrial fibrillation. Cardiovasc. Res., 2004, 62, 521-528.
3. Buch, P., Rasmussen, S., Abildstrom, S. Z. és mtsai: The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years. Eur. Heart J., 2005, 26, 145-152.
4. Camm, A. J., Savelieva, I.: Advances in antiarrhythmic drug treatment of atrial fibrillation: where do we stand now? Heart Rhythm, 2004, 1, 244-246.
5. Conway, D. S. G., Buggins, P., Hughes, E. és mtsai: Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am. Heart J., 2004, 148, 462-466.
6. Czuriga I., Édes I.: Béta-adrenerg-receptor- blokkolók a klinikai gyakorlatban. Orv. Hetil., 2004, 145, 1951-1960.
7. Csanádi Z., Fazekas T., Varró A.: A pitvarfibrilláció kezelésének nem farmakológiai lehetoségei. Orv. Hetil., 2003, 144, 1279-1289.
8. Dernellis, J., Panaretou, M.: Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur. Heart J., 2004, 25, 1100-1107.
9. Diez, J.: Profibrotic effects of angiotensin II in the heart. A matter of mediators. Hypertension, 2004, 43, 1164-1165.
10. Dabrev, D., Ravens, U.: Remodeling of cardiomyocyte ion channels in human atrial fibrillation. Basic Res. Cardiol., 2003, 98, 137-148.
11. Fazekas T.: A pitvarfibrilláció mint a hypertoniával kapcsolatos vizsgálatok végpontja. Orvostovábbképzo Szle., 2004, 11, 87-89.
12. Fazekas T.: Bizonyítékalapú antithromboticus kezelés pitvarfibrillációban. J. Am. Coll. Cardiol., (magyar kiadás) 2004, 4, 185-187.
13. Fazekas T.: A szívritmuszavarok gyógyszeres kezelésének jelenlegi lehetoségei és távlatai. Háziorv. Továbbképzo Szle., 2005, 10, 39-48.
14. Fazekas T., Csanádi Z.: A szívritmuszavarok kezelése. Klinikai bizonyítékok. Medicina Könyvkiadó, Budapest. 2004, 1-358. old.
15. Fazekas T., Csanádi Z., Varró A.: A pitvarfibrilláció patogenezise és klinikai jelentosége. Orv. Hetil., 2003, 144, 155-163.
16. Fazekas T., Csanádi Z., Varró A.: A pitvarfibrilláció gyógyszeres kezelése. Orv. Hetil., 2003, 144, 1199-1206.
17. Fazekas T., Liszkai G.: Az intravénás magnéziumszulfát hatása a kinidin kamrai proarrhythmiás aktivitására pitvarfibrilláció ban. Magy. Belorv. Arch., 2000, 53, 372-380.
18. Fazekas T., Liszkai G., Bielik H. és mtsa: Zur Geschichte des Vorhofflimmerns. Z. Kardiol., 2003, 92, 122-127.
19. Fetsch, T., Bauer, P., Engberding, R. és mtsai: Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur. Heart J., 2004, 25, 1385-1394.
20. Folkeringa, R. J., Tieleman, R. G., Crijns, H. J. G. M.: Non-antiarrhythmic drugs to prevent atrial fibrillation. Heart Rhythm, 2004, 1, 516-518.
21. Gheorghiade, M., Robbins, J. D., Lukas, M. A.: Role of carvedilol in atrial fibrillation: insights from clinical trials. Am. J. Cardiol., 2004, 93 (Suppl), 53B-57B.
22. Gilmour, R. F. Jr. Zipes, D. P.: Mechanisms of disease: new mechanisms of antiarrhythmic actions. Nature Clin. Pract., 2004, 1, 37-41.
23. Goette, A., Lendeckel, U.: Nonchannel drug targets in atrial fibrillation. Pharmacol. Therap., 2004, 102, 17-36.
24. Greenlee, R. T., Vidaillet, H.: Recent progress in the epidemiology of atrial fibrillation. Curr. Opin. Cardiol., 2005, 20, 7-14.
25. Healey, J. S., Baranchuk, A., Crystal, E. és mtsai: Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. A meta-analysis. J. Am. Coll. Cardiol., 2005, 45, 1832-1839.
26. Heidbüchel, H.: A paradigm shift in treatment of atrial fibrillation: from electrical to structural therapy? Eur. Heart J., 2003, 24, 2077-2078.
27. Hove-Madsen, L., Llach, A., Bayes-Genís, A. és mtsai: Atrial fibrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myocytes. Circulation, 2004, 110, 1358-1363.
28. Korantzopoulos, P., Kolettis, T., Kountouris, E. és mtsai: Atrial remodelling in persistent atrial fibrillation: the potential role of aldosteron. Eur. Heart J., 2004, 25, 1086-1087.
29. Leone, O., Boriani, G., Chiappini, B. és mtsai: Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation. Eur. Heart J., 2004, 25, 1237-1241.
30. Madrid, A. H., Bueno, M. G., Rebollo, J. M. G. és mtsai: Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. A prospective and randomized study. Circulation, 2002, 106, 331-336.
31. Maggioni, A. P., Latini, R., Carson, P. E. és mtsai: Valsartan Heart Failure Trial (Val-HeFT). Eur. Heart J., 2003, 24, 407, 2457 A.
32. 6 deficiency: new risk markers for nonvalvular atrial fibrillation ? Am. Heart J., 2004, 148, 456-461.
33. Mozaffarian, D., Psaty, B. M., Rimm, E. B. és mtsai: Fish intake and risk of incident atrial fibrillation. Circulation, 2004, 110, 368-373.
34. Murray, K. T., Rottman, J. N., Arbogast, P. G. és mtsai: Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm, 2004, 1, 669-675.
35. Nattel, S., Shiroshita-Takesgita, A., Cardin, S. és mtsa: Mechanisms of atrial remodeling and clinical relevance. Curr. Opin. Cardiol., 2005, 20, 21-25.
36. Pappone, C., Santinelli, V., Manguso, F. és mtsai: Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation, 2004, 109, 327-334.
37. Patten, M., Maas, R., Bauer, P. és mtsai: Suppression of paroxysmal atrial fibrillation - results of the SOPAT trial. Eur. Heart J., 2004, 25, 1395-1404.
38. Porter, K. E., Turner, N. A., Regan, D. J. O. és mtsai: Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovasc. Res., 2004, 61, 745-755.
39. 4 receptor antagonist RS-100302 in experimental atrial flutter and fibrillation. Circulation, 1999, 100, 2010-2017.
40. Ridker, P. M., Bassuk, S. S., Toth, P. P.: C-reaktív protein és kardiovaszkuláris kockázat: bizonyí tékok és klinikai alkalmazás. Curr. Atheroscler. Rep. (magyar kiadás), 2003, 5, 341-349.
41. Roy, D., Rowe, B. H., Stiell és mtsai (CRAFT Investigators): A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J. Am. Coll. Cardiol., 2004, 44, 2355-2361.
42. Shinagawa, K., Derakhchan, K., Nattel, S.: Pharmacological prevention of atrial tachycardia induced atrial remodeling as a potential therapeutic strategy. Pacing Clin. Electrophysiol., 2003, 26, 752-764.
43. +-exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling. Cardiovasc. Res., 2002, 54, 438-446.
44. Shinagawa, K., Shiroshita-Takeshita, A., Schram, G. és mtsai: Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium. Insights into the mechanism of the superior efficacy of amiodarone. Circulation, 2003, 107, 1440-1446.
45. Shinoshita-Takeshita, A., Schram, G., Lavoie, J. és mtsai: Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 2004, 110, 2313-2319.
46. Siu, C. W., Lau, C. P., Tse, H. F.: Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am. J. Cardiol., 2003, 92, 1343-1345.
47. Tamargo, J., Caballero, R., Delpon, E.: New mechanistic targets for the treatment of atrial fibrillation. In Atrial fibrillation: new therapeutic concepts. Szerk.: Papp J. Gy., Straub M., Ziegler D. IOS Press, Amsterdam, 2003, 133-155. old.
48. Thambidorai, S. K., Parakh, K., Martin, D. O. és mtsai: Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. Am. J. Cardiol., 2004, 94, 805-807.
49. Tomaselli, G. F.: Ventricularization of atrial gene expression in the fibrillating heart? Circ. Res. 2005, 96, 923-924.
50. Ueng, K. C., Tsai, T. P., Yu, W. C. és mtsai: Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur. Heart J., 2003, 24, 2090-2098.
51. Van den Berg, M. P., van Gelder, I. C., van Veldhuisen, D. J.: Depletion of atrial natriuretic peptide during longstanding atrial fibrillation. Eur. Heart J., 2004, 25, 433-437.
52. Van der Velden, H. M. W., Jongsma, H. J.: Cardiac gap junctions and connexins: their role in atrial fibrillation and potential as therapeutic targets. Cardiovasc. Res., 2002, 54, 270-279.
53. Vigmond, E. J., Tsoi, V., Arevalo, H. és mtsai: The effect of vagally induced dispersion of action potential duration on atrial arrhythmogenesis. Heart Rhythm 2004, 1, 334-344.
54. Villani, G. Q., Nollo, G., Ravelli, F. és mtsai: Effect of amiodarone on electrical remodeling in patients with persistent atrial fibrillation. Heart Rhythm, 2004, 1 (May Suppl), S219, 696A.
55. Vos, M. A.: Atrial-specific drugs: the way to treat atrial fibrillation? J. Cardiovasc. Electrophysiol., 2004, 15, 1451-1452.
56. Vyas, A. K., Moss, A. J., Olshansky, B. és mtsai: Lipid-lowering agents reduce ventricular tachyarrhythmias in MADIT-II. Heart Rhythm, 2004, 1 (May Suppl.), S264, 844A.
57. 1 in left human atrium: a potential contributor to atrial ectopy. Cardiovasc. Res., 2004, 64, 250-259.
58. Wenckebach, K. F.: Die unregelmässige Herztätigkeit und ihre klinische Bedeutung. Verlag von Wilhelm Engelmann, Leipzig/Berlin, 1914.
59. Young-Xu, Y., Jabbour, S., Goldberg, R. és mtsai: Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am. J. Cardiol., 2003, 92, 1379-1383.